An open-label study to assess safety and efficacy of SZC in paediatric patients with hyperkalaemia

Trial Identifier: D9481C00001
Sponsor: AstraZeneca
Collaborator:
Not Applicable
NCTID:: NCT03813407
Start Date: April 2019
Primary Completion Date: December 2023
Study Completion Date: December 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CA, AB Calgary, AB, CA, T3B 6A8
CA, AB Edmonton, AB, CA, T6G 1C9
CN Beijing, CN, 100020
CN Beijing, CN, 100045
CN Beijing, CN, 100034
CN Changsha, CN, 410007
CN Chengdu, CN, 610000
CN Chengdu, CN, 610041
CN Chongqing, CN, 400014
CN hangzhou, CN, 310052
CN Hefei, CN, 230001
CN Shanghai, CN, 200062
CN Shanghai, CN, 201102
GB Glasgow, GB, G51 4TF
GB Manchester, GB, M13 9WL
GB Nottingham, GB, NG7 2UH
JP Bunkyo-ku, JP, 113-8431
JP Fuchu-shi, JP, 183-8561
JP Kawasaki-shi, JP, 211-0063
JP Matsumoto-shi, JP, 390-8621
JP Nakagami-gun, JP, 903-0215
JP Saitama-Shi, JP, 330-8777
JP Sendai-Shi, JP, 989-3126
JP Shizuoka-Shi, JP, 420-8660
PL Bialystok, PL, 15-089
PL Krakow, PL, 30-663
PL Łódź, PL, 93-338
PL Warszawa, PL, 02-091
RO Bucuresti, RO, 077120
RO Bucuresti, RO, 22328
RO Cluj-Napoca, RO, 400177
RO Targu Mures, RO, 540136
RU Samara, RU, 443095
UA Dnipropetrovsk, UA, 49100
UA Kharkiv region, UA, 61075
UA Kiev, UA, 1103
UA Odesa, UA, 65038
UA Sumy, UA, 40031
UA Zaporizhzhia, UA, 69063
US, AL Birmingham, AL, US, 35233
US, GA Atlanta, GA, US, 30322
US, MD Baltimore, MD, US, 21287
US, MO Saint Louis, MO, US, 63104
US, NC Charlotte, NC, US, 28207
US, NC Winston-Salem, NC, US, 27157
US, NJ Hackensack, NJ, US, 07601
US, NY Stony Brook, NY, US, 11794
US, OH Akron, OH, US, 44308
US, WV Morgantown, WV, US, 26506-7900